Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liposarcoma | 4 | 2023 | 288 | 1.110 |
Why?
|
| Carbon-Sulfur Lyases | 6 | 2018 | 17 | 0.810 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2022 | 335 | 0.650 |
Why?
|
| Doxorubicin | 9 | 2018 | 2229 | 0.620 |
Why?
|
| Sarcoma | 8 | 2021 | 1802 | 0.570 |
Why?
|
| Salmonella typhimurium | 5 | 2018 | 348 | 0.540 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2018 | 3605 | 0.480 |
Why?
|
| Radiodermatitis | 1 | 2013 | 61 | 0.420 |
Why?
|
| Philadelphia Chromosome | 1 | 2011 | 119 | 0.370 |
Why?
|
| Blast Crisis | 1 | 2011 | 102 | 0.370 |
Why?
|
| Compartment Syndromes | 1 | 2013 | 159 | 0.360 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2011 | 52 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 350 | 0.350 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2018 | 646 | 0.350 |
Why?
|
| Deoxycytidine | 2 | 2018 | 886 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 640 | 0.320 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2019 | 169 | 0.290 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 685 | 0.270 |
Why?
|
| Bone Matrix | 2 | 2018 | 127 | 0.260 |
Why?
|
| Mice, Nude | 11 | 2018 | 3618 | 0.260 |
Why?
|
| Thiazoles | 1 | 2011 | 1529 | 0.230 |
Why?
|
| Recombinant Proteins | 5 | 2018 | 6507 | 0.210 |
Why?
|
| Pyrimidines | 3 | 2018 | 3043 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2016 | 352 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2018 | 5330 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2019 | 1163 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2016 | 562 | 0.180 |
Why?
|
| Lipoma | 1 | 2023 | 294 | 0.180 |
Why?
|
| Salmonella Infections | 2 | 2018 | 175 | 0.170 |
Why?
|
| Pseudomonas putida | 1 | 2018 | 49 | 0.150 |
Why?
|
| Bone Demineralization Technique | 1 | 2018 | 27 | 0.150 |
Why?
|
| Piperazines | 3 | 2018 | 2547 | 0.140 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 1878 | 0.140 |
Why?
|
| Spinal Fusion | 2 | 2018 | 1307 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 52 | 0.140 |
Why?
|
| Fibrosarcoma | 1 | 2018 | 313 | 0.130 |
Why?
|
| Ketones | 1 | 2017 | 183 | 0.130 |
Why?
|
| Furans | 1 | 2017 | 199 | 0.130 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 367 | 0.130 |
Why?
|
| Pyridines | 3 | 2018 | 2888 | 0.130 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2016 | 77 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2015 | 2730 | 0.120 |
Why?
|
| Melanoma | 3 | 2018 | 5702 | 0.120 |
Why?
|
| Cisplatin | 2 | 2018 | 1656 | 0.120 |
Why?
|
| Cell Tracking | 1 | 2016 | 139 | 0.120 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 2215 | 0.120 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2021 | 616 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 9407 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 385 | 0.110 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 839 | 0.110 |
Why?
|
| Curettage | 1 | 2012 | 74 | 0.100 |
Why?
|
| Osteosarcoma | 1 | 2018 | 908 | 0.100 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 2561 | 0.100 |
Why?
|
| Sarcoma, Synovial | 1 | 2013 | 157 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 2056 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 1228 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2020 | 2902 | 0.090 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2012 | 119 | 0.090 |
Why?
|
| Phthalazines | 1 | 2013 | 397 | 0.090 |
Why?
|
| Bone Transplantation | 1 | 2015 | 921 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 13644 | 0.080 |
Why?
|
| Random Allocation | 3 | 2018 | 2394 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11876 | 0.080 |
Why?
|
| Musculoskeletal Diseases | 1 | 2014 | 598 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 1608 | 0.070 |
Why?
|
| Tumor Burden | 3 | 2018 | 1902 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2018 | 2926 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3942 | 0.070 |
Why?
|
| Body Weight | 4 | 2018 | 4626 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2011 | 1838 | 0.070 |
Why?
|
| Indazoles | 2 | 2018 | 306 | 0.070 |
Why?
|
| Tibia | 1 | 2012 | 1071 | 0.060 |
Why?
|
| Humans | 28 | 2023 | 766812 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8540 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2823 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2021 | 4747 | 0.060 |
Why?
|
| Adolescent | 7 | 2019 | 88902 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2022 | 81657 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 10263 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2023 | 160 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 2952 | 0.050 |
Why?
|
| Animals | 13 | 2018 | 168939 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2018 | 2062 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 54872 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2013 | 718 | 0.050 |
Why?
|
| Mice | 8 | 2018 | 81898 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2018 | 4019 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 6105 | 0.040 |
Why?
|
| Databases, Factual | 3 | 2020 | 8065 | 0.040 |
Why?
|
| Neurofibroma | 1 | 2019 | 95 | 0.040 |
Why?
|
| Sulfonamides | 2 | 2018 | 1982 | 0.040 |
Why?
|
| Female | 13 | 2019 | 396532 | 0.040 |
Why?
|
| Prognosis | 4 | 2021 | 29959 | 0.040 |
Why?
|
| Male | 13 | 2019 | 364154 | 0.040 |
Why?
|
| Mitosis | 1 | 2023 | 1176 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2017 | 411 | 0.030 |
Why?
|
| Suction | 1 | 2018 | 268 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2019 | 10101 | 0.030 |
Why?
|
| Mutation | 2 | 2018 | 30214 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13489 | 0.030 |
Why?
|
| Cell Proliferation | 3 | 2018 | 10451 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 2925 | 0.030 |
Why?
|
| California | 1 | 2019 | 1435 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1105 | 0.030 |
Why?
|
| Ilium | 1 | 2015 | 155 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18329 | 0.030 |
Why?
|
| Aged | 8 | 2019 | 171344 | 0.030 |
Why?
|
| Taxoids | 1 | 2018 | 665 | 0.030 |
Why?
|
| Neurilemmoma | 1 | 2019 | 522 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2018 | 1088 | 0.030 |
Why?
|
| Point Mutation | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 705 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 2028 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 376 | 0.030 |
Why?
|
| Femoral Neoplasms | 1 | 2012 | 85 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3552 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 2703 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3610 | 0.020 |
Why?
|
| Pyrazines | 1 | 2016 | 1204 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2018 | 65286 | 0.020 |
Why?
|
| Imidazoles | 1 | 2016 | 1168 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2127 | 0.020 |
Why?
|
| Age Factors | 2 | 2018 | 18397 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2013 | 670 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 2391 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 4853 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1615 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 1279 | 0.020 |
Why?
|
| Middle Aged | 6 | 2019 | 223267 | 0.020 |
Why?
|
| Radius | 1 | 2012 | 441 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 22350 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 6853 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 2783 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6514 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 6306 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2019 | 24299 | 0.020 |
Why?
|
| Apoptosis | 2 | 2013 | 9514 | 0.020 |
Why?
|
| Reoperation | 1 | 2018 | 4325 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 2210 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 17089 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 4860 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2019 | 41706 | 0.020 |
Why?
|
| Adult | 5 | 2020 | 223305 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 12064 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 6548 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 4114 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 2045 | 0.010 |
Why?
|
| Young Adult | 3 | 2019 | 59939 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12536 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14653 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12985 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11218 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4652 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 36570 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 9546 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2013 | 8310 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10745 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 7585 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13276 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 3186 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8623 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 5690 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 4282 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15831 | 0.010 |
Why?
|
| Child | 2 | 2014 | 80670 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39312 | 0.010 |
Why?
|
| United States | 1 | 2020 | 72945 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 36459 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 42577 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 59548 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 21162 | 0.000 |
Why?
|
Concepts
(171)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_